Marcus Schmidt
University of Applied Sciences Mainz(DE)Johannes Gutenberg University Mainz(DE)LMU Klinikum(DE)Klinik für Frauenheilkunde(DE)University Medical Center of the Johannes Gutenberg University Mainz(DE)Max Planck Institute for Chemical Physics of Solids(DE)Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie(DE)Eberswalde University for Sustainable Development(DE)Sana Klinikum Offenbach(DE)Max Rubner Institut(DE)Charité - Universitätsmedizin Berlin(DE)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study(2014)1,891 cited
- → Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers(2014)1,018 cited
- → The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer(2008)842 cited
- → A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors(2011)722 cited
- → Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer(2021)702 cited